Zymeworks(NASDAQ) ZYME

Zymeworks makes new medicines to treat difficult diseases like cancer and autoimmune conditions. These drugs help patients whose current treatments are no longer working. The company uses specialized technology to build treatments that target specific parts of diseased cells.

A Toolkit for New Medicines

• Zanidatamab: A medicine that treats certain types of bile duct cancer; it works by targeting a specific protein called HER2 found on tumor cells.
• Antibody-Drug Conjugates: Targeted therapies that deliver powerful drugs directly to cancer cells while sparing healthy tissue; includes candidates like ZW191 and ZW251.
• Multispecific Antibodies: Medicines designed to bind to multiple targets at once to better fight cancer or inflammation; these include programs like ZW209 and ZW1528.
• Platform Licensing: Technology access granted to partners; this allows other companies to use Zymeworks tools to create their own drugs.

Joining Forces with Industry Leaders

• In October 2022, the company partnered with Jazz Pharmaceuticals to develop and sell zanidatamab globally, excluding certain Asia-Pacific territories.
• Zymeworks and BeOne Medicines expanded their collaboration to progress cancer treatments across China, South Korea, and other Asian markets.
• In March 2026, the company signed a $250 million deal with Royalty Pharma to receive upfront cash in exchange for a portion of future royalty payments.
• The company received US regulatory approval for its first product, Ziihera, in November 2024 for treating previously treated biliary tract cancer.

What Makes Zymeworks Different?

The company uses its own software and molecular modeling tools to engineer complex proteins that traditional methods cannot create. Its business model focuses on sharing the high costs of drug development with larger global partners to reduce financial risk.

The Latest Financial Results

• Revenue dropped to $2.5 million in Q4 2025, a 91.9% decrease compared to the $31 million reported in Q4 2024.
• Net loss grew to $41.2 million in Q4 2025, which is 75.3% higher than the loss in the same period of 2024.
• Operating cash flow improved to negative $10 million in Q4 2025, compared to negative $41.5 million in Q4 2024.
• Market capitalization reached $2 billion in Q4 2025, representing a 78.6% increase from the previous year.

The Big Picture

Zymeworks has transitioned from a research-focused firm to a commercial-stage company with its first approved drug. By combining internal discovery with global partnerships, it maintains a steady pipeline while managing the high costs of biotechnology.